Abstract
cdc25A, cdc25B, and cdc25C are a family of human phosphatases that activate the cyclin-dependent kinases at different points of the cell cycle. cdc25A and cdc25B have been shown to have oncogenic potential, and they have been identified as transcriptional targets of c-myc. To determine the role of cdc25 genes in the pathogenesis of human lymphomas and their possible correlation with c-myc deregulation, we have analyzed the expression of cdc25A, cdc25B, and cdc25C and c-myc genes in a series of 63 non-Hodgkin's lymphomas and 8 nonneoplastic lymphoid tissues. The mRNA levels of the three phosphatases in the nonneoplastic tissues were negative or negligible. cdc25B overexpression was detected in 35 tumors (56%). This overexpression was more frequently found in aggressive (81%) than in indolent lymphomas (36%; P < 0.01). cdc25B overexpression was also significantly associated with a higher proliferative activity of the tumors. No cdc25B gene amplification or rearrangements were detected by Southern blot analysis. A biallelic EcoRI polymorphism of cdc25B gene was identified with a similar distribution in patients with lymphoma and in a normal population. cdc25A was overexpressed in three aggressive lymphomas. No detectable cdc25C mRNA levels were seen in any of the tumors. c-myc was overexpressed in 43% of tumors, and it correlated significantly with the presence of cdc25B up-regulation. Twenty-six of 35 (74%) lymphomas with high levels of cdc25B mRNA also showed c-myc overexpression, whereas 27 of 28 (96%) tumors without detectable or with very low cdc25B expression also had undetectable c-myc levels (P < 0.0001). In addition, a significant linear correlation was found between the cdc25B and c-myc mRNA levels (r = 0.575, P < 0.001). These findings suggest that cdc25B overexpression in non-Hodkin's lymphoma may participate in the pathogenesis of aggressive variants, and it may cooperate with c-myc oncogene in the development of these tumors.
Footnotes
-
↵1 This work was supported by Comision Interministerial de Ciencia y Tecnologia (CICYT), Ministerio de Educación y Cultura Grant SAF 96/61; Marató-TV3 Càncer Grant 95/3010D, Fundación Cientffica de la Asociación Española contra el Cancer; and Generalitat de Catalunya Grant SGR 10/96. S. H. was a fellow supported by Comissió Interdepartamental de Recerca i Innovació Tecnologica (CIRIT), Generalitat de Catalunya; S. B. and M. C. were fellows supported by the Spanish Ministerio de Educación y Cultura; and L. H. was a fellow supported by Marató-TV3 Càncer and Fundació Rius i Virgili.
-
↵2 The first two authors contributed equally to this study.
-
↵3 To whom requests for reprints should be addressed, at Laboratory of Pathology, Hospital Clínic. Villarroel 170, 08036 Barcelona, Spain. Phone: 343-2275450; Fax: 343-2275717; E-mail: campo@medicina.ub.es.
- Received January 5, 1998.
- Accepted March 4, 1998.
- ©1998 American Association for Cancer Research.